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Introduction

Differential Diagnosis

Metformin is a first line oral medication for diabetes mellitus
shown to decrease cardiovascular morbidity and mortality.
Though the prevalence of metformin-associated lactic
acidosis (MALA) is low, mortality is high, ranging from
25-50%. Therefore, it presents a diagnostic challenge
that is critical to identify, particularly in patients with renal
impairment at baseline. Traditionally patients with creatinine
greater than 1.5 mg/dL have been excluded from using
metformin; however, metformin might be acceptable in
some patients with chronic kidney disease (CKD).

The differential was broad including septic shock, toxin
ingestion, cardiogenic shock, and intracranial abnormality.
Drug toxicity was ruled out as her urine drug screen and
alcohol level were negative. Severe sepsis was ruled out when
cultures (urine, blood, bronchoalveolar lavage) were negative.
CT chest, abdomen, and pelvis did not show any source of
infection. CT head was within normal limits. A transthoracic
echocardiogram did not show significant abnormalities. Given
her elevated anion gap metabolic acidosis with concomitant
osmolar gap, a diagnosis of MALA was made.

Case Presentation:
A 69 year old female with a past medical history of diabetes
mellitus, hypertension, breast cancer, and no chronic
kidney disease was sent to the hospital by her rehabilitation
facility secondary to her being found unresponsive. This
was in the presence of decreased appetite and impaired
mobility limiting her ability to feed herself in the 2 weeks
prior to hospital admission. Her medications included
metformin, insulin glargine, anastrazole, and hydrochlorothiazide. She had nausea and vomiting the night prior
to admission. Despite her decreased oral intake, she
continued taking her full dose of metformin and insulin
throughout that two week period.
On arrival to the emergency room, her vitals were rectal
temperature 90.6° F, heart rate 66 beats per minute,
blood pressure 60/40 mmHg, respiratory rate 25 breaths
per minute, and oxygen saturation 88% on room air. Her
Glasgow Coma Scale was 2 with physical exam findings
significant for limited withdrawal to noxious stimuli. Her
initial labs were significant for bicarbonate of 2 mEq/L
(normal range 24-32 mEq/L), potassium of 6.7 mEq/L
(normal range 3.5-5.0 mEq/L), blood urea nitrogen of 110
mg/dL (normal range 7-26 mg/dL), creatinine of 9.7 mg/
dL (normal range 0.7-1.4mg/dL) with a baseline of 0.7 mg/
dL 2 months ago, and lactate of 26 mmol/L (normal range
0.5-2.2 mmol/L). A venous blood gas was significant for a
pH of 6.65. Plasma metformin level was not available.

Outcome and Follow Up
Patient was intubated and admitted to the medical
intensive care unit. She was empirically started on broadspectrum antibiotics, stress dose steroids, intravenous
fluids, and vasopressors for presumed septic shock. Given
her low bicarbonate level, a bicarbonate drip was started,
and nephrology was consulted for acute renal failure
and metabolic acidosis management. The nephrology
team initiated her on continuous veno-venous hemofiltration (CVVH) therapy. She had 3 days of CVVH, after
which she was transitioned to intermittent hemodialysis.
Patient’s urine output gradually improved throughout her
hospital stay. Upon discharge, she was alert, oriented, and
conversing appropriately.

Discussion
Metformin is renally cleared and therefore accumulates in
states of decreased creatinine clearance. It also inhibits
mitochondrial electron transport, thereby increasing
anaerobic metabolism and lactate production.1 It has
been proposed that in acute kidney injury, metformin
levels accumulate, contributing to worsening lactic
acidosis, which further compounds nausea and vomiting,
and thereby reducing renal perfusion.2 The incidence of
MALA is thought to be 1-5 cases per 100,000 patient years
but can be as high as 30 cases per 100,000 patient years.3
Mortality ranges from 25-50%.4
The 5 characteristics highly suggestive of MALA are: severe
acidemia (pH < 7.1) with an anion gap greater than 20
mEq/L (normal anion gap ≤ 12 mEq/L), very low serum
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bicarbonate (7 +/- 4 mEq/L), markedly elevated lactic acid
(12.4 +/- 8 mmol/L), history of metformin ingestion, and
history of renal insufficiency.1,5 With infectious and other
drug toxicities ruled out in this patient, MALA was the most
likely cause of her lactic acidosis as the patient met all 5
aforementioned points. We propose that this patient, in
the presence of decreased oral intake in the weeks prior
to her presentation, developed acute kidney injury, which
decreased her ability to clear metformin. Consequently,
she started developing lactic acidosis, which likely
worsened any nausea or vomiting, further exacerbating
her acute renal failure leading to anuria.
Given the lack of randomized control trials in the study of
MALA, much of the existing literature on MALA are case
series, retrospective studies, and observations. The goal
in the acute management of MALA is to provide airway,
breathing, and circulatory support and to correct the
underlying acidosis with possible intravenous bicarbonate
and/or renal replacement therapy.6
A retrospective analysis study compared cases of severe
acidosis with pH < 7.0 secondary to MALA and lactic
acidoses of other origins. Despite the pH being lower in the
former group, the mortality was 100% in the latter group as
compared to 50% in the former. This shows that despite a
greater degree of acidosis and renal failure in MALA patients,
early recognition and aggressive medical therapy including
renal replacement therapy improves the survival.7
A recently published retrospective study looked at the
incidence of MALA in those with and without impaired
renal function. The 77,601 identified patients were divided
into different groups based on glomerular filtration rate
(GFR): normal, mildly reduced, moderately reduced, or
severely reduced. They found an incidence of 10.37 per
100,000 patient years. What is more significant is that they
did not find a significant difference in the development of
MALA among the 4 groups.8 This calls for more awareness
amongst general internists such that impending signs
of MALA should be recognized earlier. A recent review
article suggests that given the mild association between
metformin and lactic acidosis, metformin can be used in
those with impaired renal function but should be dosed by
GFR secondary to metformin’s varied benefits.9
Prognosis of MALA is more favorable than other etiologies
of lactic acidosis.1,10 This may be secondary to the absence
of a critical underlying condition causing lactic acidosis
such as severe ischemia. Rather the lactic acidosis is a result
of toxic drug accumulation, which can be successfully
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removed by renal replacement therapy.10 Furthermore,
though our patient did not have any CKD at baseline, she
should have been counseled on stopping her metformin
during periods of poor appetite or dehydration. Physicians
need to be comfortable and knowledgeable with using
metformin alongside medications that interfere with renal
hemodynamic regulation such as angiotensin-convertingenzyme inhibitors, aldosterone receptor blockers, and
nonsteroidal anti-inflammatory drugs.3

Key Points
Metformin is currently a first-line agent in the management
of diabetes. Though it can cause metformin-associated
lactic acidosis, the prevalence is relatively low. High clinical
suspicion is, however, important. In those taking metformin
and presenting with lactate greater than 15 mmol/L and pH
less than 7, MALA must be strongly considered. To prevent
MALA, patients on metformin should be counseled on its use
in states of potential kidney injury such as volume depletion
as was the case in our patient. Overall, patients who have
MALA should receive aggressive resuscitation methods
including fluid repletion, airway protection, vasopressors,
intravenous bicarbonate, and/or renal replacement therapy
depending on the severity of the acidosis.
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